<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Actinic cheilitis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Actinic cheilitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Actinic cheilitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christen Mowad, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">June K Robinson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4041685036"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Actinic cheilitis, also called "solar cheilitis" or "solar cheilosis," is a premalignant disorder of the lip caused by chronic sun exposure [<a href="#rid1">1-6</a>]. It is most common on the lower lip in persons with light skin type, in outdoor workers, and in geographic areas with high ultraviolet irradiation [<a href="#rid1">1,4,7-10</a>]. Actinic cheilitis shares a common pathogenesis with actinic keratosis. However, the risk of progression to squamous cell carcinoma (SCC) appears to be higher for actinic cheilitis than for actinic keratosis [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/13712.html" rel="external">"Actinic keratosis: Epidemiology, clinical features, and diagnosis"</a>.)</p><p>This topic will discuss the clinical features, diagnosis, and management of actinic cheilitis. Actinic keratosis and other forms of cheilitis are discussed separately. Other premalignant oral lesions are also discussed separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13712.html" rel="external">"Actinic keratosis: Epidemiology, clinical features, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13654.html" rel="external">"Cheilitis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5572.html" rel="external">"Oral lesions", section on 'Oral potentially malignant disorders'</a>.)</p><p></p><p class="headingAnchor" id="H3551093791"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>Actinic cheilitis is most common in geographic areas with high ultraviolet irradiation, in outdoor workers, and in persons with light skin types. Males are more frequently affected than females [<a href="#rid11">11,12</a>]. Reported prevalence rates among individuals with high levels of occupational exposure to ultraviolet radiation (eg, fishermen, farmers) range from 10 to 40 percent [<a href="#rid7">7,8,13,14</a>]. Chronic exposure to solar radiation is the main risk factor for actinic cheilitis. In a Spanish, multicenter study including 410 patients aged ≥45 years with actinic cheilitis, independent risk factors for actinic cheilitis were outdoor working for &gt;25 years, age ≥60 years, light skin phototype, and personal history of nonmelanoma skin cancer [<a href="#rid15">15</a>].</p><p>Actinic cheilitis may occur at an early age in patients with genetic conditions associated with increased susceptibility to solar damage (eg, xeroderma pigmentosum, oculocutaneous albinism) [<a href="#rid1">1,16-18</a>].</p><p class="headingAnchor" id="H687714534"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Actinic cheilitis initially presents as a persistent area of dryness and desquamation, typically located on the lower lip, which is likely to receive more ultraviolet radiation exposure than the upper lip  (<a class="graphic graphic_picture graphicRef119030" href="/z/d/graphic/119030.html" rel="external">picture 1E</a>) [<a href="#rid19">19</a>]. On palpation, these lesions have a characteristic "sandpapery" feel to the touch.</p><p>Atrophic changes, blurred demarcation of the vermilion border, erythema, edema, hyperkeratotic (leukoplakia-like) plaques, ulceration, and crusting may be seen in more advanced lesions  (<a class="graphic graphic_picture graphicRef79589 graphicRef131103 graphicRef68057 graphicRef67012" href="/z/d/graphic/79589.html" rel="external">picture 1A-D</a>). Lesions are usually solitary, but multiple or diffuse lesions can occur. </p><p>Other signs of actinic skin damage, including actinic keratoses, solar lentigines, and elastosis, are commonly noted in patients with actinic cheilitis [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H2102295691"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of actinic cheilitis is mainly based on clinical examination and history. A skin biopsy may be needed in select cases to rule out squamous cell carcinoma (SCC) [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H2671206814"><span class="h2">Clinical</span><span class="headingEndMark"> — </span>The diagnosis of actinic cheilitis is, in most cases, clinical. Features suggestive of actinic cheilitis include persistent lip dryness and desquamation; hyperkeratotic plaques; focal or diffuse, atrophic changes; blurring of vermilion border; erosions; or ulceration  (<a class="graphic graphic_picture graphicRef79589 graphicRef119030 graphicRef68057 graphicRef131103 graphicRef67012" href="/z/d/graphic/79589.html" rel="external">picture 1A-E</a>). A history of chronic sun exposure, particularly in outdoor workers (eg, farmers, fishermen, construction workers), supports the clinical diagnosis.</p><p class="headingAnchor" id="H4208657540"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>A lip biopsy is <strong>not</strong> routinely performed in patients with a history of chronic sun exposure and early, obvious changes of actinic cheilitis (eg, persistent dryness and scaling of the lip, characteristic "sandpapery" feel to the touch, mild atrophy). However, a biopsy is warranted in patients presenting with hyperkeratotic (leukoplakia-like) or nodular areas, with or without erosions or ulceration, that are suspicious for SCC.</p><p>Since microscopic changes suggestive of SCC may not occur homogeneously in the involved area, a single punch biopsy may not be an accurate method for precise diagnosis [<a href="#rid21">21</a>]. Rather, an elliptical incision biopsy in the thickest part of the lesion is preferred.</p><p class="headingAnchor" id="H1508018185"><span class="h2">Histopathology</span><span class="headingEndMark"> — </span>Histopathologic changes of actinic cheilitis include acanthosis, hyperkeratosis, focal areas of atrophy, and a variable degree of architectural changes and keratinocyte atypia  (<a class="graphic graphic_picture graphicRef91126" href="/z/d/graphic/91126.html" rel="external">picture 2</a>) [<a href="#rid22">22</a>]. A dermal, inflammatory infiltrate predominantly composed of lymphocytes, with occasional plasma cells and eosinophils, can also be seen. Solar elastosis is a frequent and important secondary finding [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H3822827070"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The clinical and histopathologic differential diagnosis of actinic cheilitis includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Squamous cell carcinoma of the lip</strong> – Actinic cheilitis with severe, cytologic atypia and an intense, inflammatory infiltrate may be difficult to differentiate from squamous cell carcinoma (SCC). Moreover, changes of SCC may be focal and go undetected in inadequate biopsy specimens, such as those obtained by small punch biopsy. If vermilionectomy is performed as treatment, serial sections of the entire specimen should be examined. Keratinocytic dysplasia involving the full thickness of the epidermis with atypical, pleomorphic cells indicates SCC in situ. Invasive SCC typically shows dysplastic keratinocytes involving the full thickness of the epidermis and dermal invasion. (See  <a class="medical medical_review" href="/z/d/html/16225.html" rel="external">"Cutaneous squamous cell carcinoma (cSCC): Clinical features and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lupus erythematosus</strong> – Atrophic actinic cheilitis may resemble discoid lupus erythematosus clinically and histologically  (<a class="graphic graphic_picture graphicRef91127" href="/z/d/graphic/91127.html" rel="external">picture 3</a>). However, the presence of vacuolization of the basal layer; follicular plugging; and patchy, periappendageal infiltrate differentiates lupus erythematosus from actinic cheilitis. (See  <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Discoid lupus erythematosus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lichen planus</strong> – Lip involvement of lichen planus typically shows a reticular, white pattern  (<a class="graphic graphic_picture graphicRef86886" href="/z/d/graphic/86886.html" rel="external">picture 4</a>) and is usually associated with oral buccal mucosal lesions. On histologic examination, lichen planus shows damage of basal keratinocytes with multiple apoptotic cells (Civatte bodies) and a band-like, lymphocytic infiltrate in the upper dermis. (See  <a class="medical medical_review" href="/z/d/html/15285.html" rel="external">"Oral lichen planus: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other primary lip diseases</strong> – Several inflammatory lip diseases, such as plasma cell cheilitis, cheilitis glandularis, and cheilitis granulomatosa, may share clinical features with actinic cheilitis  (<a class="graphic graphic_picture graphicRef78861 graphicRef67657 graphicRef91212" href="/z/d/graphic/78861.html" rel="external">picture 5A-C</a>). Histologic examination of a lip biopsy clarifies the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/13654.html" rel="external">"Cheilitis"</a>.)</p><p></p><p class="headingAnchor" id="H3253147649"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>There is no general consensus on the management of actinic cheilitis. Treatments that are commonly used include topical medications (eg, topical <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>, <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a>), destructive therapies (eg, liquid nitrogen, electrodessication, chemical peels, laser therapy, photodynamic therapy [PDT]), and surgery (vermilionectomy) [<a href="#rid24">24-35</a>]. Evidence for the efficacy of these treatments is limited to a few small, randomized trials and several uncontrolled clinical studies [<a href="#rid24">24,31,36</a>]. </p><p>The choice of treatment is made in the individual patient, based upon the extent and severity of the disease, clinical experience, and patient preference. Our approach is described below  (<a class="graphic graphic_algorithm graphicRef131496" href="/z/d/graphic/131496.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H4220846854"><span class="h2">General measures</span><span class="headingEndMark"> — </span>Reinforcing the use of sun protection measures, including wearing a wide-brimmed hat and using lip balms containing broad-spectrum sunscreens multiple times per day, is of key importance in the ongoing management of patients with actinic cheilitis. Cessation of tobacco use, both smoked and smokeless, should also be encouraged.</p><p class="headingAnchor" id="H1368339622"><span class="h2">Focal mild to moderate actinic cheilitis</span><span class="headingEndMark"> — </span>Observation and conservative treatments, including lip sunscreens and sun avoidance, are reasonable choices for the motivated patient with mild actinic cheilitis (focal erythema, desquamation, and/or atrophy of the vermilion border) who is willing to commit to regular follow-up visits to monitor for possible progression and adhere to daily sunscreen application to the lips  (<a class="graphic graphic_algorithm graphicRef131496" href="/z/d/graphic/131496.html" rel="external">algorithm 1</a>).</p><p>If a decision is made to treat, we suggest cryotherapy with liquid nitrogen for focal lesions of mild to moderate cheilitis [<a href="#rid31">31</a>]. Cryotherapy is widely available, rapid, inexpensive, and can be performed without local anesthesia. Adverse effects of cryotherapy include pain, edema, and scarring.</p><p>In cases of incomplete clearance at three to six months, retreatment with additional cryosurgery or initiation of topical field therapy may be undertaken. (See <a class="local">'Topical "field therapy"'</a> below.)</p><p>There is little direct evidence supporting the use of cryotherapy for the treatment of actinic cheilitis [<a href="#rid31">31</a>]. In one study, 37 patients with 53 histologically confirmed actinic cheilitis lesions of the lower lip were treated with liquid nitrogen using the paintbrush technique [<a href="#rid37">37</a>]. Recurrence was noted after two and three years of follow-up in two patients, of whom one developed squamous cell carcinoma (SCC).</p><p class="headingAnchor" id="H387762821"><span class="h2">Multifocal or diffuse mild to moderate actinic cheilitis</span></p><p class="headingAnchor" id="H723489128"><span class="h3">Topical "field therapy"</span><span class="headingEndMark"> — </span>For patients with multifocal or diffuse mild to moderate actinic cheilitis, we suggest field therapy with topical <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> or <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a> as first-line therapy  (<a class="graphic graphic_algorithm graphicRef131496" href="/z/d/graphic/131496.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical </strong><strong>fluorouracil</strong> – <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">Fluorouracil</a> 1% or 5% cream is applied twice a day for two to four weeks. Adverse effects of treatment include pain, erythema and edema of the lips, erosions, and ulcerations [<a href="#rid26">26</a>]. Although topical fluorouracil has the potential to treat subclinical disease in adjacent areas ("field therapy"), the discomfort associated with treatment may cause poor adherence to treatment in many patients. Recurrence after treatment with topical fluorouracil has been reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imiquimod</strong> – <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">Imiquimod</a> is an alternative to topical <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> for the treatment of multifocal or diffuse mild to moderate actinic cheilitis. Imiquimod 5% cream is applied to the involved area three times per week for four to six weeks. Imiquimod 2.5% or 3.75% cream is used on a schedule of daily application for two weeks, rest period for two weeks, and then another two weeks of daily application. Adverse effects included erythema, induration, erosions, and ulcerations.</p><p></p><p>We typically reassess patients three to six months after starting treatment. Persistent lesions and thickened/hyperkeratotic areas should be biopsied and further treatment planned, based on histopathologic findings. (See <a class="local">'Biopsy'</a> above.)</p><p>There is very limited evidence from small, observational studies supporting the efficacy of topical <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> and <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a> for actinic cheilitis [<a href="#rid24">24</a>]. Indirect evidence for their efficacy is derived from studies in patients with actinic keratosis of the skin [<a href="#rid36">36</a>].</p><p>In a small study comparing different treatment modalities (ie, topical <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>, chemical peel, lip shave, laser therapy) in patients with actinic cheilitis involving &gt;50 percent of the lower lip, recurrence was observed in 7 of 10 patients treated with topical fluorouracil after a median follow-up time of 50 months [<a href="#rid35">35</a>]. In a series of 15 patients with actinic cheilitis treated with topical <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a>, all patients showed clinical clearing four weeks after discontinuing treatment [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H3959436985"><span class="h3">Photodynamic therapy</span><span class="headingEndMark"> — </span>Photodynamic therapy (PDT) is a treatment option for patients who do not tolerate topical <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> or <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a>. However, its efficacy appears to be relatively low [<a href="#rid39">39-41</a>] (see  <a class="medical medical_review" href="/z/d/html/13647.html" rel="external">"Photodynamic therapy"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>In a systematic review of 15 case series including 242 patients with actinic cheilitis treated with PDT, 139 of 223 patients (62 percent) had complete clinical response at 3 to 30 months, and 57 of 121 patients (47 percent) demonstrated histologic cure 1.5 to 18 months after treatment [<a href="#rid39">39</a>]. In a subsequent report of 16 patients treated with two sessions of <a class="drug drug_general" data-topicid="16481" href="/z/d/drug information/16481.html" rel="external">methyl aminolevulinate</a> (MAL)-PDT with a similar rate of clinical clearing, none achieved histologic cure [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A similar clinical response rate with PDT (69 percent) was reported in a subsequent systematic review that included 239 patients [<a href="#rid24">24</a>]. Of note, a complete clinical response was reported in 19 of 23 patients (83 percent) treated with daylight PDT.</p><p></p><p>Ablative laser-assisted PDT may be more effective than standard PDT for the treatment of actinic cheilitis. In a small comparative study, 33 patients with actinic cheilitis were treated with a single session of ablative fractional laser (AFL) therapy immediately followed by MAL-PDT or with two sessions of MAL-PDT one week apart [<a href="#rid43">43</a>]. At 12 months, the complete clinical and histologic response rates were 85 and 29 percent in the AFL plus MAL-PDT and MAL-PDT only groups, respectively.</p><p class="headingAnchor" id="H4091935971"><span class="h2">Severe actinic cheilitis</span><span class="headingEndMark"> — </span>For patients presenting with severe, diffuse actinic cheilitis with hyperkeratotic (leukoplakia-like) or nodular areas, ulceration, or fissuring, treatment options include laser ablation and surgical excision  (<a class="graphic graphic_algorithm graphicRef131496" href="/z/d/graphic/131496.html" rel="external">algorithm 1</a>).</p><p>The choice between these approaches is based on the grade of dysplasia assessed by pretreatment histopathologic examination (see <a class="local">'Biopsy'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with severe actinic cheilitis without evidence of high-grade dysplasia or cancer on biopsy, we suggest laser ablation with carbon dioxide (CO<sub>2</sub>) laser or erbium:yttrium aluminum garnet (Er:YAG) laser rather than surgical excision or topical therapies. Adverse effects of laser ablation include a prolonged healing time and post-treatment hypo- or hyperpigmentation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with severe actinic cheilitis with evidence of high-grade dysplasia, surgical excision (vermilionectomy) followed by defect repair by primary closure or mucosal advancement flap is the treatment of choice [<a href="#rid44">44,45</a>]. In contrast with laser ablation, vermilionectomy allows for the histopathologic examination of the entire vermilion and margins as well as the detection of occult SCC not identified by a previous biopsy [<a href="#rid21">21</a>]. The procedure may be associated with significant postoperative complications, including bruising, wound dehiscence, partial flap necrosis, scarring, and loss of normal lip contour [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/3407.html" rel="external">"Treatment of stage I and II (early) head and neck cancer: The oral cavity", section on 'Lip (squamous cell carcinoma)'</a>.)</p><p></p><p>A few studies, mainly case series, have evaluated the efficacy of laser ablation and surgical excision for actinic cheilitis:</p><p class="bulletIndent1"><span class="glyph">●</span>In a systematic review and meta-analysis of nine observational studies and one randomized trial (283 patients) comparing surgical (vermilionectomy or laser therapy) and nonsurgical (<a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a>, topical <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">diclofenac</a>, PDT) treatments for actinic cheilitis, the weighted remission rate among 122 patients treated with surgical excision or laser therapy was 93 percent (95% CI 85.5-96.5 percent), with a weighted recurrence rate of 8.4 percent (95% CI 4.5-15.1 percent) [<a href="#rid46">46</a>]. For nonsurgical therapies, the weighted remission and recurrence rates were 66 and 19 percent, respectively. However, these results must be interpreted with caution because the included studies were small, and none of them directly compared surgical versus nonsurgical therapies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 2021 systematic review, four of the five included studies using CO<sub>2</sub> laser ablation did not report any recurrences [<a href="#rid47">47</a>]. Recurrence occurred in 13 percent of patients in one study that used a single-pass, modified protocol for CO<sub>2</sub> laser ablation. No recurrences were reported in four studies with 106 patients treated with surgical excision.</p><p></p><p class="headingAnchor" id="H864863385"><span class="h1">PROGNOSIS AND FOLLOW-UP</span><span class="headingEndMark"> — </span>The risk of malignant transformation of actinic cheilitis into squamous cell carcinoma (SCC) is unknown. In one study, the estimated transformation rate was approximately 3 percent [<a href="#rid48">48</a>]. However, as patients with actinic cheilitis have an increased risk of developing lip cancer, regular clinical surveillance and repeated biopsies of suspicious areas are recommended.</p><p class="headingAnchor" id="H749472595"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Strict and continued sun protection is an important aspect of preventing the progression of actinic cheilitis to squamous cell carcinoma (SCC) and the development of further disease. Sun protection measures include sun avoidance, wearing wide-brimmed hats, and daily use of lip products containing broad-spectrum sunscreens [<a href="#rid6">6</a>]. Smoking and chewing tobacco cessation is recommended. (See  <a class="medical medical_review" href="/z/d/html/13751.html" rel="external">"Selection of sunscreen and sun-protective measures"</a>.)</p><p class="headingAnchor" id="H1713148154"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/123054.html" rel="external">"Society guideline links: Actinic keratosis"</a>.)</p><p class="headingAnchor" id="H2244279481"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Actinic cheilitis, also called "solar cheilitis" or "solar cheilosis," is a premalignant disorder of the lip caused by chronic exposure to ultraviolet radiation. It occurs most frequently on the lower lip of light-skinned individuals with high levels of occupational sun exposure (eg, fishermen, farmers) and is more common in males than in females. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Actinic cheilitis initially presents as a persistent area of dryness and scaling typically located on the lower lip  (<a class="graphic graphic_picture graphicRef119030" href="/z/d/graphic/119030.html" rel="external">picture 1E</a>). More advanced lesions show atrophy, blurred demarcation of the vermilion border, erythema, edema, ulceration, and crusting  (<a class="graphic graphic_picture graphicRef79589 graphicRef68057 graphicRef67012" href="/z/d/graphic/79589.html" rel="external">picture 1A, 1C-D</a>). (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of actinic cheilitis is usually clinical. However, a biopsy may be necessary for ulcerated or crusted lesions that are suspicious for squamous cell carcinoma (SCC). (See <a class="local">'Diagnosis'</a> above and <a class="local">'Biopsy'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Topical, destructive, or surgical therapies are used for the treatment of actinic cheilitis. The choice of treatment is made in the individual patient, based upon the extent and severity of the disease, clinical experience, and patient preference. Our approach is as follows  (<a class="graphic graphic_algorithm graphicRef131496" href="/z/d/graphic/131496.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest cryotherapy with liquid nitrogen for patients with limited mild to moderate actinic cheilitis (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, observation is a reasonable choice for the motivated patient with mild actinic cheilitis (focal erythema, desquamation, and/or atrophy of the vermilion border) who is willing to commit to regular follow-up visits to monitor for possible progression and adhere to daily sunscreen application to the lips. (See <a class="local">'Focal mild to moderate actinic cheilitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with multifocal or diffuse mild to moderate actinic cheilitis, we suggest field therapy with topical <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> or <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a> rather than photodynamic therapy (PDT) or laser therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, PDT is a treatment option for patients who do not tolerate topical fluorouracil or imiquimod. (See <a class="local">'Multifocal or diffuse mild to moderate actinic cheilitis'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with severe actinic cheilitis presenting with hyperkeratotic (leukoplakia-like) areas with or without ulceration should undergo a lip biopsy prior to treatment to determine the presence and grade of dysplasia and whether invasive SCC is present. (See <a class="local">'Biopsy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with severe diffuse actinic cheilitis without evidence of high-grade dysplasia or cancer on biopsy, we suggest laser ablation with carbon dioxide (CO<sub>2</sub>) laser or erbium:yttrium aluminum garnet (Er:YAG) laser rather than surgical excision or topical therapies (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Surgical excision (vermilionectomy), which allows for the histopathologic examination of the entire vermilion, is the treatment of choice for actinic cheilitis with high-grade dysplasia on biopsy. (See <a class="local">'Severe actinic cheilitis'</a> above and  <a class="medical medical_review" href="/z/d/html/3407.html" rel="external">"Treatment of stage I and II (early) head and neck cancer: The oral cavity", section on 'Lip (squamous cell carcinoma)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As patients with actinic cheilitis have an increased risk of developing lip cancer, regular clinical surveillance and repeated biopsies of suspicious areas are recommended. Sun protection measures and tobacco smoking or chewing cessation are important aspects of lip cancer prevention. (See <a class="local">'Prognosis and follow-up'</a> above and <a class="local">'Prevention'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Jadotte YT, Schwartz RA. Solar cheilosis: an ominous precursor: part I. Diagnostic insights. J Am Acad Dermatol 2012; 66:173.</a></li><li><a class="nounderline abstract_t">Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 2007; 36:575.</a></li><li><a class="nounderline abstract_t">Wetzel SL, Wollenberg J. Oral Potentially Malignant Disorders. Dent Clin North Am 2020; 64:25.</a></li><li><a class="nounderline abstract_t">Rogers RS 3rd, Bekic M. Diseases of the lips. Semin Cutan Med Surg 1997; 16:328.</a></li><li><a class="nounderline abstract_t">Savage NW, McKay C, Faulkner C. Actinic cheilitis in dental practice. Aust Dent J 2010; 55 Suppl 1:78.</a></li><li><a class="nounderline abstract_t">Cavalcante AS, Anbinder AL, Carvalho YR. Actinic cheilitis: clinical and histological features. J Oral Maxillofac Surg 2008; 66:498.</a></li><li><a class="nounderline abstract_t">de Souza Lucena EE, Costa DC, da Silveira EJ, Lima KC. Prevalence and factors associated to actinic cheilitis in beach workers. Oral Dis 2012; 18:575.</a></li><li><a class="nounderline abstract_t">Miranda AM, Soares LG, Ferrari TM, et al. Prevalence of actinic cheilitis in a population of agricultural sugarcane workers. Acta Odontol Latinoam 2012; 25:201.</a></li><li><a class="nounderline abstract_t">Martins-Filho PR, Da Silva LC, Piva MR. The prevalence of actinic cheilitis in farmers in a semi-arid northeastern region of Brazil. Int J Dermatol 2011; 50:1109.</a></li><li><a class="nounderline abstract_t">de Santana Sarmento DJ, da Costa Miguel MC, Queiroz LM, et al. Actinic cheilitis: clinicopathologic profile and association with degree of dysplasia. Int J Dermatol 2014; 53:466.</a></li><li><a class="nounderline abstract_t">Lopes ML, Silva Júnior FL, Lima KC, et al. Clinicopathological profile and management of 161 cases of actinic cheilitis. An Bras Dermatol 2015; 90:505.</a></li><li><a class="nounderline abstract_t">Moreira P, Assaf AV, Cortellazzi KL, et al. Social and behavioural associated factors of actinic cheilitis in rural workers. Oral Dis 2021; 27:911.</a></li><li><a class="nounderline abstract_t">de Oliveira Ribeiro A, da Silva LC, Martins-Filho PR. Prevalence of and risk factors for actinic cheilitis in Brazilian fishermen and women. Int J Dermatol 2014; 53:1370.</a></li><li><a class="nounderline abstract_t">Junqueira JL, Bönecker M, Furuse C, et al. Actinic cheilitis among agricultural workers in Campinas, Brazil. Community Dent Health 2011; 28:60.</a></li><li><a class="nounderline abstract_t">Rodríguez-Blanco I, Flórez Á, Paredes-Suárez C, et al. Actinic Cheilitis Prevalence and Risk Factors: A Cross-sectional, Multicentre Study in a Population Aged 45 Years and Over in North-west Spain. Acta Derm Venereol 2018; 98:970.</a></li><li><a class="nounderline abstract_t">Maia HC, Pinto NA, Pereira Jdos S, et al. Potentially malignant oral lesions: clinicopathological correlations. Einstein (Sao Paulo) 2016; 14:35.</a></li><li><a class="nounderline abstract_t">Lookingbill DP, Lookingbill GL, Leppard B. Actinic damage and skin cancer in albinos in northern Tanzania: findings in 164 patients enrolled in an outreach skin care program. J Am Acad Dermatol 1995; 32:653.</a></li><li><a class="nounderline abstract_t">Feller L, Wood NH, Motswaledi MH, et al. Xeroderma pigmentosum: a case report and review of the literature. J Prev Med Hyg 2010; 51:87.</a></li><li><a class="nounderline abstract_t">Kaugars GE, Pillion T, Svirsky JA, et al. Actinic cheilitis: a review of 152 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 88:181.</a></li><li><a class="nounderline abstract_t">Rodríguez-Blanco I, Flórez Á, Paredes-Suárez C, et al. Actinic Cheilitis: Analysis of Clinical Subtypes, Risk Factors and Associated Signs of Actinic Damage. Acta Derm Venereol 2019; 99:931.</a></li><li><a class="nounderline abstract_t">Menta Simonsen Nico M, Rivitti EA, Lourenço SV. Actinic cheilitis: histologic study of the entire vermilion and comparison with previous biopsy. J Cutan Pathol 2007; 34:309.</a></li><li><a class="nounderline abstract_t">Vieira RA, Minicucci EM, Marques ME, Marques SA. Actinic cheilitis and squamous cell carcinoma of the lip: clinical, histopathological and immunogenetic aspects. An Bras Dermatol 2012; 87:105.</a></li><li><a class="nounderline abstract_t">Santana T, Nagata G, Saturno JL, Trierveiler M. Histopathological features of photodamage and mast cell infiltrate in actinic cheilitis with different grades of epithelial dysplasia. J Cutan Pathol 2020; 47:592.</a></li><li><a class="nounderline abstract_t">Lai M, Pampena R, Cornacchia L, et al. Treatments of actinic cheilitis: A systematic review of the literature. J Am Acad Dermatol 2020; 83:876.</a></li><li><a class="nounderline abstract_t">Zaiac M, Clement A. Treatment of actinic cheilitis by photodynamic therapy with 5-aminolevulinic acid and blue light activation. J Drugs Dermatol 2011; 10:1240.</a></li><li><a class="nounderline abstract_t">Jadotte YT, Schwartz RA. Solar cheilosis: an ominous precursor part II. Therapeutic perspectives. J Am Acad Dermatol 2012; 66:187.</a></li><li><a class="nounderline abstract_t">Sotiriou E, Lallas A, Goussi C, et al. Sequential use of photodynamic therapy and imiquimod 5% cream for the treatment of actinic cheilitis: a 12-month follow-up study. Br J Dermatol 2011; 165:888.</a></li><li><a class="nounderline abstract_t">Armenores P, James CL, Walker PC, Huilgol SC. Treatment of actinic cheilitis with the Er:YAG laser. J Am Acad Dermatol 2010; 63:642.</a></li><li><a class="nounderline abstract_t">Fai D, Romano I, Cassano N, Vena GA. Methyl-aminolevulinate photodynamic therapy for the treatment of actinic cheilitis: a retrospective evaluation of 29 patients. G Ital Dermatol Venereol 2012; 147:99.</a></li><li><a class="nounderline abstract_t">Ishida CE, Ramos-e-Silva M. Cryosurgery in oral lesions. Int J Dermatol 1998; 37:283.</a></li><li><a class="nounderline abstract_t">Shah AY, Doherty SD, Rosen T. Actinic cheilitis: a treatment review. Int J Dermatol 2010; 49:1225.</a></li><li><a class="nounderline abstract_t">Sotiriou E, Apalla Z, Chovarda E, et al. Photodynamic therapy with 5-aminolevulinic acid in actinic cheilitis: an 18-month clinical and histological follow-up. J Eur Acad Dermatol Venereol 2010; 24:916.</a></li><li><a class="nounderline abstract_t">Barrado Solís N, Molés Poveda P, Lloret Ruiz C, et al. Ingenol mebutate gel treatment for actinic cheilitis: report of four cases. Dermatol Ther 2015; 28:79.</a></li><li><a class="nounderline abstract_t">Flórez Á, Batalla A, de la Torre C. Management of actinic cheilitis using ingenol mebutate gel: A report of seven cases. J Dermatolog Treat 2017; 28:149.</a></li><li><a class="nounderline abstract_t">Robinson JK. Actinic cheilitis. A prospective study comparing four treatment methods. Arch Otolaryngol Head Neck Surg 1989; 115:848.</a></li><li><a class="nounderline abstract_t">Gupta AK, Paquet M, Villanueva E, Brintnell W. Interventions for actinic keratoses. Cochrane Database Syst Rev 2012; 12:CD004415.</a></li><li><a class="nounderline abstract_t">Lubritz RR, Smolewski SA. Cryosurgery cure rate of premalignant leukoplakia of the lower lip. J Dermatol Surg Oncol 1983; 9:235.</a></li><li><a class="nounderline abstract_t">Smith KJ, Germain M, Yeager J, Skelton H. Topical 5% imiquimod for the therapy of actinic cheilitis. J Am Acad Dermatol 2002; 47:497.</a></li><li><a class="nounderline abstract_t">Yazdani Abyaneh MA, Falto-Aizpurua L, Griffith RD, Nouri K. Photodynamic therapy for actinic cheilitis: a systematic review. Dermatol Surg 2015; 41:189.</a></li><li><a class="nounderline abstract_t">Fai D, Romanello E, Brumana MB, et al. Daylight photodynamic therapy with methyl-aminolevulinate for the treatment of actinic cheilitis. Dermatol Ther 2015; 28:355.</a></li><li><a class="nounderline abstract_t">Levi A, Hodak E, Enk CD, et al. Daylight photodynamic therapy for the treatment of actinic cheilitis. Photodermatol Photoimmunol Photomed 2019; 35:11.</a></li><li><a class="nounderline abstract_t">Chaves YN, Torezan LA, Lourenço SV, Neto CF. Evaluation of the efficacy of photodynamic therapy for the treatment of actinic cheilitis. Photodermatol Photoimmunol Photomed 2017; 33:14.</a></li><li><a class="nounderline abstract_t">Choi SH, Kim KH, Song KH. Efficacy of ablative fractional laser-assisted photodynamic therapy for the treatment of actinic cheilitis: 12-month follow-up results of a prospective, randomized, comparative trial. Br J Dermatol 2015; 173:184.</a></li><li><a class="nounderline abstract_t">Sand M, Altmeyer P, Bechara FG. Mucosal advancement flap versus primary closure after vermilionectomy of the lower lip. Dermatol Surg 2010; 36:1987.</a></li><li><a class="nounderline abstract_t">Barry RB, McKenzie J, Berg D, Langtry JA. Direct primary closure without undermining in the repair of vermilionectomy defects of the lower lip. Br J Dermatol 2012; 167:1092.</a></li><li><a class="nounderline abstract_t">Carvalho MV, de Moraes SLD, Lemos CAA, et al. Surgical versus non-surgical treatment of actinic cheilitis: A systematic review and meta-analysis. Oral Dis 2019; 25:972.</a></li><li><a class="nounderline abstract_t">Trager MH, Farmer K, Ulrich C, et al. Actinic cheilitis: a systematic review of treatment options. J Eur Acad Dermatol Venereol 2021; 35:815.</a></li><li><a class="nounderline abstract_t">Dancyger A, Heard V, Huang B, et al. Malignant transformation of actinic cheilitis: A systematic review of observational studies. J Investig Clin Dent 2018; 9:e12343.</a></li></ol></div><div id="topicVersionRevision">Topic 119010 Version 6.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22243721" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Solar cheilosis: an ominous precursor: part I. Diagnostic insights.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17944749" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Nomenclature and classification of potentially malignant disorders of the oral mucosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31735231" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Oral Potentially Malignant Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9421227" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Diseases of the lips.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20553248" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Actinic cheilitis in dental practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18280383" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Actinic cheilitis: clinical and histological features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22335283" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevalence and factors associated to actinic cheilitis in beach workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23230642" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prevalence of actinic cheilitis in a population of agricultural sugarcane workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22126872" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The prevalence of actinic cheilitis in farmers in a semi-arid northeastern region of Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24320079" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Actinic cheilitis: clinicopathologic profile and association with degree of dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26375219" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinicopathological profile and management of 161 cases of actinic cheilitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32790925" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Social and behavioural associated factors of actinic cheilitis in rural workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25039599" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prevalence of and risk factors for actinic cheilitis in Brazilian fishermen and women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21485236" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Actinic cheilitis among agricultural workers in Campinas, Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30085328" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Actinic Cheilitis Prevalence and Risk Factors: A Cross-sectional, Multicentre Study in a Population Aged 45 Years and Over in North-west Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27074232" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Potentially malignant oral lesions: clinicopathological correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7896957" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Actinic damage and skin cancer in albinos in northern Tanzania: findings in 164 patients enrolled in an outreach skin care program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21155411" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Xeroderma pigmentosum: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10468463" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Actinic cheilitis: a review of 152 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31197386" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Actinic Cheilitis: Analysis of Clinical Subtypes, Risk Factors and Associated Signs of Actinic Damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17381801" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Actinic cheilitis: histologic study of the entire vermilion and comparison with previous biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22481658" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Actinic cheilitis and squamous cell carcinoma of the lip: clinical, histopathological and immunogenetic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32133685" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Histopathological features of photodamage and mast cell infiltrate in actinic cheilitis with different grades of epithelial dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31400450" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Treatments of actinic cheilitis: A systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22052302" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Treatment of actinic cheilitis by photodynamic therapy with 5-aminolevulinic acid and blue light activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22243722" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Solar cheilosis: an ominous precursor part II. Therapeutic perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21916880" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Sequential use of photodynamic therapy and imiquimod 5% cream for the treatment of actinic cheilitis: a 12-month follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20846565" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Treatment of actinic cheilitis with the Er:YAG laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22370573" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Methyl-aminolevulinate photodynamic therapy for the treatment of actinic cheilitis: a retrospective evaluation of 29 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9585902" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cryosurgery in oral lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20964646" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Actinic cheilitis: a treatment review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20028448" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Photodynamic therapy with 5-aminolevulinic acid in actinic cheilitis: an 18-month clinical and histological follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25545762" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Ingenol mebutate gel treatment for actinic cheilitis: report of four cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27241280" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Management of actinic cheilitis using ingenol mebutate gel: A report of seven cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2736096" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Actinic cheilitis. A prospective study comparing four treatment methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23235610" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Interventions for actinic keratoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6826879" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cryosurgery cure rate of premalignant leukoplakia of the lower lip.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12271290" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Topical 5% imiquimod for the therapy of actinic cheilitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25627629" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Photodynamic therapy for actinic cheilitis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26179312" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Daylight photodynamic therapy with methyl-aminolevulinate for the treatment of actinic cheilitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30066408" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Daylight photodynamic therapy for the treatment of actinic cheilitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27864997" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Evaluation of the efficacy of photodynamic therapy for the treatment of actinic cheilitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25400009" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Efficacy of ablative fractional laser-assisted photodynamic therapy for the treatment of actinic cheilitis: 12-month follow-up results of a prospective, randomized, comparative trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21040126" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Mucosal advancement flap versus primary closure after vermilionectomy of the lower lip.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22708844" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Direct primary closure without undermining in the repair of vermilionectomy defects of the lower lip.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29908101" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Surgical versus non-surgical treatment of actinic cheilitis: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33251620" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Actinic cheilitis: a systematic review of treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29863311" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Malignant transformation of actinic cheilitis: A systematic review of observational studies.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
